UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Where there is inflammation, treatment may reduce disability progression – No

Multiple sclerosis, 2018-12, Vol.24 (14), p.1810-1812

2018

Volltextzugriff (PDF)

Treating active MS following induction therapies

Multiple sclerosis, 2022, Vol.28 (3_SUPPL), p.38-38

2022

Volltextzugriff (PDF)

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Multiple sclerosis, 2022-07, Vol.28 (8), p.1277-1285

2022

Volltextzugriff (PDF)

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

Multiple sclerosis, 2011-07, Vol.17 (7), p.867-875

2011

Volltextzugriff (PDF)

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Multiple sclerosis, 2012-02, Vol.18 (2), p.143-152

2012

Volltextzugriff (PDF)

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Multiple sclerosis, 2021-10, Vol.27 (11), p.1760-1770

2021

Volltextzugriff (PDF)

There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Yes

Multiple sclerosis, 2012-07, Vol.18 (7), p.927-929

Edan, Gilles

2012

Volltextzugriff (PDF)

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Multiple sclerosis, 2023-05, Vol.29 (6), p.719-730

2023

Volltextzugriff (PDF)

Oral rather than intravenous corticosteroids should be used to treat MS relapses – Yes

Multiple sclerosis, 2017-07, Vol.23 (8), p.1056-1058

2017

Volltextzugriff (PDF)

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Multiple sclerosis, 2020-07, Vol.26 (8), p.924-935

2020

Volltextzugriff (PDF)

Richard E Gonsette (1929–2014)

Multiple sclerosis, 2015-04, Vol.21 (5), p.540-540

2015

Volltextzugriff (PDF)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

Multiple sclerosis, 2016-11, Vol.22 (13), p.1719-1731

2016

Volltextzugriff (PDF)

An excessive risk of suicide may no longer be a reality for multiple sclerosis patients

Multiple sclerosis, 2017-05, Vol.23 (6), p.864-871

2017

Volltextzugriff (PDF)

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Multiple sclerosis, 2021-03, Vol.27 (3), p.479-482

2021

Volltextzugriff (PDF)

‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study

Multiple sclerosis, 2013-04, Vol.19 (4), p.458-465

2013

Volltextzugriff (PDF)

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

Multiple sclerosis, 2020-12, Vol.26 (14), p.1898-1906

2020

Volltextzugriff (PDF)

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

Multiple sclerosis, 2016-04, Vol.22 (4), p.533-543

2016

Volltextzugriff (PDF)

Deciphering multiple sclerosis disability progression in the elderly: a multicenter cohort study

Multiple sclerosis, 2022, Vol.28 (3_SUPPL), p.450-450

2022

Volltextzugriff (PDF)

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Multiple sclerosis, 2021-01, Vol.27 (1), p.90-96

2021

Volltextzugriff (PDF)

Discontinuation of high- versus middle-efficacy disease-modifying treatment in middle-aged patients with multiple sclerosis

Multiple sclerosis, 2022, Vol.28 (3_SUPPL), p.911-912

2022

Volltextzugriff (PDF)

Focal and diffuse cervical spinal cord damage in patients with early relapsing–remitting MS: A multicentre magnetisation transfer ratio study

Multiple sclerosis, 2019-07, Vol.25 (8), p.1113-1123

2019

Volltextzugriff (PDF)

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Multiple sclerosis, 2019-04, Vol.25 (4), p.565-573

2019

Volltextzugriff (PDF)

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up

Multiple sclerosis, 2018-12, Vol.24 (14), p.1852-1861

2018

Volltextzugriff (PDF)

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

Multiple Sclerosis Journal, 2020-08, Vol.26 (9), p.1031-1044

2020

Volltextzugriff (PDF)

Long-term effect of interferon-beta use in real-world settings on disability progression a series of 2,451 relapsing-remitting multiple sclerosis patients, Rennes, France

Multiple sclerosis, 2017, Vol.23, p.633-634

2017

Volltextzugriff (PDF)

1 – 25 von 1.072

Suche als RSS-Feed

Aktive Filter

SpracheArabisch

SpracheCroatian

PublikationsformBuchkapitel

Zeitschrift / SerieMultiple Sclerosis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.072)
Mit Volltextzugriff
(1.072)

Publikationsform

Artikel
(1.072)

Sprache

Englisch
(1.072)
Japanisch
(103)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Multiple Sclerosis Journal
(117)
Mult Scler
(1)

Menü

Weitere Dienste

Einstellungen

Where there is inflammation, treatment may reduce disability progression – No

Treating active MS following induction therapies

Body mass index as a predictor of MS activity and progression among participants in BENEFIT

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Cumulative effects of therapies on disability in relapsing multiple sclerosis

There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Yes

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study

Oral rather than intravenous corticosteroids should be used to treat MS relapses – Yes

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

Richard E Gonsette (1929–2014)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

An excessive risk of suicide may no longer be a reality for multiple sclerosis patients

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study

High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

Deciphering multiple sclerosis disability progression in the elderly: a multicenter cohort study

Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries

Discontinuation of high- versus middle-efficacy disease-modifying treatment in middle-aged patients with multiple sclerosis

Focal and diffuse cervical spinal cord damage in patients with early relapsing–remitting MS: A multicentre magnetisation transfer ratio study

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

USPIO-positive MS lesions are associated with greater tissue damage than gadolinium-positive-only lesions during 3-year follow-up

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

Long-term effect of interferon-beta use in real-world settings on disability progression a series of 2,451 relapsing-remitting multiple sclerosis patients, Rennes, France

Aktive Filter

Suchergebnisse filtern